Search Results

Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today reported corporate updates and financial results for the first quarter ended March 31, 2024.

Marker Therapeutics, Inc. (Nasdaq: MRKR) today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference.

Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today reported recent corporate developments and financial results for the year ended December 31, 2023.

Marker Therapeutics, Inc. today announced a restructuring of its clinical programs and a strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline.

Marker Therapeutics, Inc. today reported a clinical update on the APOLLO study.

Marker Therapeutics, Inc. reported that Geoffrey Shouse, D.O., Ph.D., the Principal Investigator at City of Hope National Medical Center in Duarte, CA, was invited to present his clinical experience from the APOLLO study at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada.

NMDP BioTherapies℠ (formerly known as Be The Match BioTherapies) will present a poster at this year’s International Society for Cell & Gene Therapy annual meeting in Vancouver, Canada (ISCT 2024 ) sharing results of a study of the impacts of delayed whole blood processing on the stability of infectious disease marker analytes during donor qualification for allogeneic cell therapies.

Marker Therapeutics, Inc. announced that the Company’s management team will participate in Biotech Showcase and present at the 19th Annual Non-Dilutive Funding Summit.